Greatmark Investment Partners Inc. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Greatmark Investment Partners Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 88,440 shares of the company’s stock after selling 132 shares during the quarter. Johnson & Johnson makes up 2.4% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 15th biggest holding. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $13,775,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Diamant Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 1.0% in the third quarter. Diamant Asset Management Inc. now owns 23,091 shares of the company’s stock valued at $3,596,000 after purchasing an additional 226 shares in the last quarter. Milestone Investment Advisors LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $535,000. Fidelis Capital Partners LLC increased its position in Johnson & Johnson by 17.8% during the third quarter. Fidelis Capital Partners LLC now owns 13,181 shares of the company’s stock worth $2,052,000 after buying an additional 1,992 shares in the last quarter. Pinnacle West Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 5.6% in the third quarter. Pinnacle West Asset Management Inc. now owns 14,620 shares of the company’s stock worth $2,277,000 after acquiring an additional 775 shares during the last quarter. Finally, Austin Private Wealth LLC boosted its stake in shares of Johnson & Johnson by 42.8% during the third quarter. Austin Private Wealth LLC now owns 8,695 shares of the company’s stock valued at $1,354,000 after acquiring an additional 2,604 shares during the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

NYSE JNJ opened at $156.76 on Monday. The firm has a market capitalization of $377.37 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The company’s 50 day moving average price is $158.20 and its 200 day moving average price is $158.73.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.35 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Raymond James boosted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Tuesday, February 6th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Get Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.